Trial · NCT02408315
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Delivery | from study entry until delivery- anticipated 3 days | number of hours from placement of study drug to delivery Cesarean delivery for fetal non--reassurance indication |
| Primary | Number of Participants With Cesarean Deliveries Based on Fetal Non-Reassurance Indications | from study entry until delivery- anticipated 3 days | Rate of cesarean deliveries performed for fetal non-reassurance as the indication |
| Secondary | Number of Vaginal Deliveries That Occurred Within 24 Hours | from study entry until delivery- anticipated 3 days | rate of achieving vaginal delivery within 24 hours |
| Secondary | Number of Participants Who Had Uterine Hyperstimulation | from study entry until delivery- anticipated 3 days | Presence of uterine hyperstimulation, tachysystole as defined as 6 uterine contractions in a 10 minute period |
| Secondary | Number of Neonatal Intensive Care Unit (NICU) Admission | from study entry until discharge of newborn- anticipated up to 28 days | Admission to NICU |
| Secondary | Number of Doses Misoprostol Used | from study entry until delivery- anticipated 3 days | Number of doses of misoprostol needed |
| Secondary | Uterine Rupture | from study entry until delivery- anticipated 3 days | Presence of uterine rupture |
| Secondary | Dose of Oxytocin Used for Augmentation | from study entry until delivery- anticipated 3 days | dose of oxytocin used for augmentation of labor |
| Secondary | Number of Participants With Neonatal Cord Gases Measured | from study entry until delivery- anticipated 3 days | cord gases from newborn |
| Other | Pharmacokinetic Profiling of Misoprostol | from study entry until delivery- anticipated 3 days | pharmacokinetic parameters (Area under the curve, half-life, maximum concentration) measured over first 2 study drug doses |
| Other | Participant Satisfaction | from study entry until discharge- anticipated 5 days | participant satisfaction with labor induction and preference for method of drug administration. This will use a questionnaire developed for this study with some similarity to the referenced Nassar study below. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408315/registered